Corcept Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Corcept Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Corcept Therapeutics Inc Strategy Report
- Understand Corcept Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Corcept Therapeutics Inc patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
AU2021214938A1 | Application | Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMs) and antibody checkpoint inhibitors | A61K31/337; A61K31/4745; A61K31/513; A61K31/7068; A61K45/06; A61P35/00; C07K16/28; C07K2317/76; C07K2317/92 | September 08, 2022 |
AU2021220763A1 | Application | Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator | A61K31/337; A61K31/4745; A61K45/06; A61P35/00 | September 08, 2022 |
EP3897654A4 | Search Report | BEHANDLUNG VON HYPERCOAGULOPATHIE BEI CUSHING-SYNDROM DURCH VERABREICHUNG VON GLUCOCORTICOID-REZEPTORMODULATOREN | A61K2300/00; A61K31/4745; A61K31/567; A61K45/06; A61P7/00; A61P7/02; A61P7/04; G01N33/743; G01N33/86 | September 07, 2022 |
IL294862A | Application | Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (sgrms) and antibody checkpoint inhibitors | A61K31/337; A61K31/4745; A61K31/513; A61K31/7068; A61K45/06; A61P35/00; C07K16/28; C07K2317/76; C07K2317/92 | September 01, 2022 |
IL294953A | Application | Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator | A61K31/337; A61K31/4745; A61K45/06; A61P35/00 | September 01, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer